Jinhe Biotechnology Co., Ltd. Class A

As of June 30, 2026, Jinhe Biotechnology Co., Ltd. Class A carries a market capitalization of 3.56B, placing it among publicly traded companies globally. Its enterprise value stands at 5.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jinhe Biotechnology Co., Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Jinhe Biotechnology Co., Ltd. Class A has 769.50M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Jinhe Biotechnology Co., Ltd. Class A maintains a current ratio of 1.18, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Jinhe Biotechnology Co., Ltd. Class A recorded 65.49M in income tax expense.

As of the close on October 23, 2026, Jinhe Biotechnology Co., Ltd. Class A's stock has declined approximately 27.10% over the past 52 weeks. The 50-day moving average sits at 5.19, while the 200-day moving average is 5.59.

As of June 30, 2026, Jinhe Biotechnology Co., Ltd. Class A holds 701.07M in cash and equivalents against 2.36B in total debt, resulting in a net debt position of 844.39M. Total book value stands at 2.27B, with working capital of 335.84M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Jinhe Biotechnology Co., Ltd. Class A paid dividends of 0.16 per share.

Jinhe Biotechnology Co., Ltd. Class A's most recent stock split took place on May 17, 2016 with a 2:5 split ratio.